PART I . Overview We are a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Our engineered viruses are designed to induce a systemic anti-tumor response due to induction of immunogenic cell death within the tumor microenvironment, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. This is inte...
Q2 FY2026 — expected 2026-08-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-103134 | EDGAR | 125K words |
| 2025-03-13 | 2024-12-31 | 0000950170-25-038803 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-037637 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0000950170-23-010760 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0000950170-22-004857 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-279086 | EDGAR | 81K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108450 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-069833 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-126767 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-095784 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059118 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061566 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040984 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020873 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024197 | EDGAR | — |
| 2022-08-05 | 2022-06-30 | 0000950170-22-014970 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009479 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001193125-26-103126 | EDGAR | 3K words |
| 2026-02-23 | 0001193125-26-062490 | EDGAR | — |
| 2026-02-19 | 0001193125-26-059334 | EDGAR | — |
| 2025-12-05 | 0001193125-25-308719 | EDGAR | — |
| 2025-11-13 | 0001193125-25-279072 | EDGAR | — |
| 2025-10-14 | 0001193125-25-238254 | EDGAR | — |
| 2025-08-21 | 0000950170-25-110682 | EDGAR | — |
| 2025-08-14 | 0000950170-25-108448 | EDGAR | — |
| 2025-06-24 | 0001193125-25-145405 | EDGAR | — |
| 2025-06-23 | 0001193125-25-144204 | EDGAR | — |
116 total filings indexed. 89 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001841387 |
| Ticker | CADL |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.candeltx.com |
| Listed | 2021-07-27 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report